Ideaya Biosciences (IDYA) announced the clearance of an investigational new drug, or IND, application with the FDA for the initiation of a Phase 1 clinical trial to evaluate IDE275, a potential Werner Helicase inhibitor. IDE275 has demonstrated synthetic lethality preclinically in the high microsatellite instability biomarker setting, and the Phase 1 clinical trial will enroll patients having tumors characterized by MSI-High.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences announces IDE397 expansion data
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls
- Ideaya Biosciences initiated with a Buy at UBS
- Ideaya Biosciences initiated with an Overweight at Cantor Fitzgerald
- Ideaya Biosciences management to meet with Oppenheimer